Skip to main
BLLN

Billiontoone Inc (BLLN) Stock Forecast & Price Target

Billiontoone Inc (BLLN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

BillionToOne is in a strong position to capitalize on the growing demand for liquid biopsies, with a unique technology and successful revenue growth. Their expansion into the prenatal and MRD testing markets, along with their strong operating structure and competitive pricing, gives them an advantage over their competitors. However, they will need to navigate challenges in reimbursement and competition in order to maintain their market position and continue their growth trajectory.

Bears say

BillionToOne is a molecular diagnostics company that has achieved profitability in just its 6th year of commercial launch, with a strong focus on growth initiatives. However, its revenue and profitability are highly dependent on government reimbursement and third-party payors, and the company faces competition in both the women's health and oncology markets. Additionally, its release of a new MRD test may not generate reimbursement until the end of 2027. While the company has a large untapped market and opportunities for market share gain, its closest comparables trade at an average of 10.2x 2026 EV/revenues, making it an expensive stock.

Billiontoone Inc (BLLN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Billiontoone Inc (BLLN) Forecast

Analysts have given Billiontoone Inc (BLLN) a Buy based on their latest research and market trends.

According to 7 analysts, Billiontoone Inc (BLLN) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Billiontoone Inc (BLLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.